Lyase Variant for High Enantiomeric Excess (S)-PAC Synthesis
Solution Overview
Problem
Current methods for the asymmetric synthesis of (S)-Phenylacetylcarbinol (S-PAC) fail to achieve high optical purities greater than 89% ee, often produce by-products, and require expensive separation of chiral product mixtures, using either chemical or enzymatic processes that are inefficient with unchiral starting materials.
Innovation Solution
A variant of the lyase ApPDC-E469G, where tryptophan at position 543 is replaced by a sterically smaller amino acid, along with DNA encoding these enzymes and vectors, is used to catalyze the reaction of benzaldehyde and pyruvate or acetaldehyde to produce (S)-Phenylacetylcarbinol with high enantiomeric excess without by-products, utilizing whole cells or crude cell extracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chemical asymmetric synthesis methods are used to produce (S)-PAC, then the production process is established, but the enantiomeric excess only reaches 68-86% and additional separation steps are required
Solution Approach 1:
The patent applies parameter changes by modifying the enzyme's amino acid sequence (substituting residues at positions 469 and 543) to alter its catalytic properties. This enables the enzyme to achieve >99% ee in the carboligation reaction, eliminating the need for complex separation processes that were required with chemical methods that only achieved 68-86% ee.
Solution Approach 2:
The patent replaces chemical asymmetric synthesis methods with an engineered enzymatic system. The mechanical/chemical approach (chemical catalysts requiring separation) is substituted with a biological catalyst (engineered pyruvate decarboxylase) that provides inherent stereoselectivity, eliminating the need for additional separation equipment and processes.
2Manufacturing precision
If the enzyme ApPDC-E469G is used for asymmetric synthesis of (S)-PAC, then the enantiomeric excess reaches 89%, but the production in whole cells only achieves ~43% ee
Solution Approach 1:
The patent applies parameter changes by introducing a second amino acid substitution (W543A or W543V) in addition to the E469G mutation. This dual mutation strategy optimizes the enzyme's performance in whole-cell systems, raising the ee from 43% to >99% while maintaining productive catalysis in the complex cellular environment.
Solution Approach 2:
The patent creates a composite enzymatic system by combining multiple mutations (E469G + W543A/V) within the same protein structure. This composite approach integrates the benefits of both mutations: E469G provides the base level of stereoselectivity, while W543A/V optimizes performance in whole-cell systems, achieving synergistic enhancement of catalytic efficiency and enantiomeric excess.
3Manufacturing precision
If high optical purity (>89% ee) is achieved through enzymatic synthesis, then the product quality is improved, but expensive separation of chiral product mixtures is still required
Solution Approach 1:
The patent applies parameter changes through directed evolution and site-directed mutagenesis to optimize the enzyme's stereoselectivity. By substituting amino acids at positions 469 and 543, the enzyme achieves >99% ee, which is sufficient to eliminate expensive chromatographic separation processes that would be required for lower ee products.
Solution Approach 2:
The patent converts the enzyme's natural tendency to produce mixed enantiomers (a harmful aspect) into a highly selective catalyst for single enantiomer production (a beneficial aspect). Through rational design and mutagenesis, the enzyme's active site is optimized to exclusively accommodate and transform one enantiomer, turning a limitation into a powerful selective advantage.
4Ease of manufacture
If unchiral starting materials are used for asymmetric synthesis, then the cost of raw materials is reduced, but achieving high optical purity becomes more difficult
Solution Approach 1:
The patent replaces chemical asymmetric synthesis methods (which struggle to achieve high ee from unchiral materials) with an engineered enzymatic system. The biological catalyst provides inherent stereoselectivity through its chiral active site architecture, enabling high optical purity (>99% ee) to be achieved directly from unchiral substrates without requiring expensive chiral auxiliaries or resolution steps.
Solution Approach 2:
The patent applies parameter changes by modifying the enzyme's amino acid sequence to optimize its stereoselective catalysis of unchiral substrates. The mutations at positions 469 and 543 tune the enzyme's active site geometry and electronic properties, enabling it to discriminate between transition states leading to different enantiomers, thereby achieving high optical purity from achiral starting materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves enantiomeric excesses of 97% using isolated enzymes, 95% with whole cells, and 94% with crude cell extracts, eliminating the need for expensive separation and using inexpensive unchiral starting materials, thereby overcoming the limitations of prior art.
Implementation Method 1
A variant of the lyase ApPDC-E469G, where tryptophan at position 543 is replaced by a sterically smaller amino acid, along with DNA encoding these enzymes and vectors, is used to catalyze the reaction of benzaldehyde and pyruvate or acetaldehyde to produce (S)-Phenylacetylcarbinol with high enantiomeric excess
Data Source
Figure 1
AI summary
The invention relates to a lyase and a lyase-encoding DNA, to vectors containing the DNA and to a method for the asymmetric synthesis of (S)-phenylacetylcarbinol. According to the invention, a lyase is provided, in which tryptophan is replaced with an amino acid at position 543 in protein ApPDC-E469G, said protein being modified with respect to the wild type of Aceobacter pasteurianus, or in which it is less space-filling than tryptophan. According to the invention, deoxyribonucleic acids are furthermore provided, which encode the lyase. (S)-phenylacetylcarbinol can be produced with the lyase according to the invention from the educts benzaldehyde and pyruvate or acetaldehyde with an enantiomeric excess of at least 94 %.